IRON

IRON

USD

Disc Medicine Inc. Common Stock

$86.060+3.050 (3.674%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$83.010

High

$87.125

Low

$83.010

Volume

0.64M

Company Fundamentals

Market Cap

3.2B

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

0.43M

Exchange

NGM

Currency

USD

52-Week Range

Low $30.82Current $86.060High $95.95

Related News

GlobeNewswire

Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for

View more
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
Analyst Upgrades

Stifel Reinstates Buy on Disc Medicine, Announces $125 Price Target

Stifel analyst Stephen Willey reinstates Disc Medicine with a Buy and announces $125 price target.

View more
Stifel Reinstates Buy on Disc Medicine, Announces $125 Price Target
GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for

View more
Disc Medicine to Participate in Upcoming Investor Conferences
Analyst Upgrades

Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $115

Morgan Stanley analyst Sean Laaman maintains Disc Medicine with a Overweight and raises the price target from $90 to $115.

View more
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $115